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SUMMARY
Prion diseases are caused by conversion of a normally folded, nonpathogenic isoform of the prion
protein (PrPC) to a misfolded, pathogenic isoform (PrPSc). Prion inoculation experiments in mice
expressing homologous PrPC molecules on different genetic backgrounds displayed different
incubation times, indicating that the conversion reaction may be influenced by other gene products.
To identify genes that contribute to prion pathogenesis, we analyzed prion incubation times in mice
in which the gene product was inactivated, knocked out or overexpressed. We tested 20 gene
candidates, because their products either colocalize with PrP, are associated with Alzheimer’s
disease, are elevated during prion disease, or function in PrP-mediated signaling, PrP glycosylation,
or protein maintenance. Whereas some of the candidates tested may have a role in the normal function
of PrPC, our data show that many genes previously implicated in prion replication have no discernable
effect on the pathogenesis of prion disease. While most genes tested did not significantly affect
survival times, ablation of amyloid beta (A4) precursor protein (App) or interleukin 1 receptor, type
I (Il1r1), and transgenic overexpression of human superoxide dismutase 1 (SOD1) prolonged
incubation times by 13%, 16%, and 19%, respectively.
INTRODUCTION
Prion diseases are fatal neurodegenerative disorders of humans and animals that uniquely
present as sporadic, genetic, or infectious maladies (Prusiner, 2007). These diseases are caused
by prions, which are formed from the conformational conversion of a ubiquitous and
noninfectious isoform of the prion protein (PrPC) to disease-associated and infectious isoforms
(PrPSc). Prions are unprecedented pathogens because nucleic acids are not involved in their
replication (Safar et al., 2005). Genetic experiments have shown that the Prnp gene, which
encodes PrPC, controls the incubation period in prioninfected mice (Carlson et al., 1986). In
addition, evidence from experiments in inbred mice expressing homologous PrPC molecules
show` that genes other than Prnp modify the incubation period to some extent (Carlson et al.,
1988, Stephenson et al., 2000). Similarly, studies in the yeast Saccharomyces cerevisiae show
that chaperones of the Hsp104, Hsp70, and Hsp40 groups are critical for propagation of the
yeast prions [PSI+], [URE3], and [PIN+] (reviewed in (Wickner et al., 2007)).
Based on these studies, any gene product involved in the formation of PrPSc should affect the
onset of prion disease if knocked out, inactivated, or overexpressed as demonstrated for PrP
itself (Prusiner et al., 1993, Prusiner et al., 1990). Many genes have been suggested to contribute
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to prion replication, of which we tested 20 (Table 1). Mice in which the candidate gene product
was inactivated, ablated or overexpressed were inoculated and incubation times relative to
control mice recorded (Table 2–Table 5). To determine whether differences in incubation
period were significant, we developed a novel statistical method accounting for
interexperiment variability. While most of the tested genes did not play a role in prion disease,
we show here that mice deficient for amyloid beta (A4) precursor protein (App) or interleukin
1 receptor, type I (Il1r1) had prolonged incubation times by 13% and 16%, respectively.




Most mouse lines have been described previously. App−/− mice lack amyloid beta (A4)
precursor protein (App) (Zheng et al., 1995). Aplp2−/− mice lack amyloid beta (A4) precursor-
like protein 2 (Aplp2) (von Koch et al., 1997). Tg(APP)6209Kahs mice, originally designated
Tg(HuAPP695.WTmyc)6209, express human APP695 (Hsiao et al., 1995). Tg(APOE3) and
Tg(APOE4) mice, originally named Tg(NSE-apoE3) and Tg(NSE-apoE4), express the ε3 or
the ε4 allele of human apolipoprotein E (APOE) driven by the neuron-specific enolase (NSE)
promoter on a C57BL/6J-Apoe−/− (C57BL6J-Apoetm1Unc) background (Raber et al., 1998). Tg
(Tgfb1) mice express porcine transforming growth factor-β1 (TGF-β1) driven by the glial
fibrillary acidic protein (GFAP) promoter on a SJL/J background (Wyss-Coray et al., 1995).
Tgfb1+/− mice with one ablated Tgfb1 allele were generated on the NIH/Ola background (Shull
et al., 1992). Ccr2−/− and Ccr5−/− mice lack chemokine (C-C motif) receptors 2 (CCR2) and
CCR5, respectively (Kuziel et al., 2003, Kuziel et al., 1997). (TβRIIΔk)+/− × Tg(tTA)+/−
Prnp+/− mice neuronally express a transdominant negative kinase-deficient mutant of TGF-β
receptor II (TβRIIΔk) and are deficient in TGF-β signaling (Tesseur et al., 2006). Msra−/− mice
lack methionine sulfoxide reductase A (Moskovitz et al., 2001). Tg(SOD1)3Cje mice
overexpress human superoxide dismutase 1, soluble (SOD1); their littermate controls are
(BALB/c × C57BL/6J)F1 × (C57BL/6J × DBA/2)F1 (Epstein et al., 1987). Tg(HSP70) mice
express human heat shock protein 70 (Hsp70); their wt controls are (CBA × C57BL/6J)F1 mice
(Plumier et al., 1995). Mgat3−/− mice lack mannoside-b1,4-N-acetylglucosaminyltransferase
III (Yang et al., 2000). Cd9−/− mice lack the CD9 antigen (LeNaour et al., 2000). Cav1−/− mice
lack caveolin-1 (Williams et al., 2003). Fyn−/− mice lack fyn proto-oncogene (Fyn) (Grant et
al., 1992). Tg(Fyn) mice overexpress wt mouse Fyn directed by the calcium/calmodulin-
dependent protein kinase IIα promoter on a C57BL/6 background (line N8) (Kojima et al.,
1997). Ptpra−/− mice lack protein tyrosine phosphatase, receptor type, A (RPTPα) (Petrone et
al., 2003). Prnd-ablated mice on an FVB background were produced in our laboratory as
described in the online supplement.
The following mice were obtained from The Jackson Laboratory: Apoe−/− mice on C57BL/6J
background (C57BL/6J-Apoetm1Unc); interleukin 10 (IL-10)–knockout mice on a C57BL/6J
background, denoted B6-IL10−/− mice (B6.129P2-Il10tm1Cgn/J); IL-10–knockout mice on a
129S6 background, denoted 129-IL10−/− mice (129-Il10tm1Cgn/J); tumor necrosis factor–
deficient mice, denoted Tnf−/− mice (B6.129S6-Tnftm1Gkl/J); mice lacking Tnf receptor
superfamily, members 1a (TNF-R1) and 1b (TNF-R2), denoted Tnfrsf1a−/− Tnfrsf1b−/− mice
(B6; 129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J); and Interleukin 1 receptor, type I-knockout mice,
denoted Il1r1−/− mice (B6;129S1-Il1r1tm1Roml/J). C57BL/6J,129S1/SvlmJ, B6129SF2/J, and
FVB/N mice were obtained as controls. Crossing Tnfrsf1a+/+ Tnfrsf1b+/+ mice with
B6129SF2/J mice gave Tnfrsf1a+/− Tnfrsf1b+/− mice. Crossing Il1r1+/+ mice with B6129SF2/
J mice yielded Il1r1+/− mice. The genetic status of the progeny was determined using protocols
from the Jackson Laboratory.
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Prion isolates and transmission
CD1 mouse–adapted RML, Me7, and 301V prions were used as inocula. RML and Me7 were
originally derived from sheep with scrapie and have been serially passaged in mice for many
generations; 301V was derived from a cow with BSE and passaged into VM mice (Bruce et
al., 1994, Chandler, 1961, Dickinson & Meikle, 1969). Brain homogenates (10% wt/vol) in
PBS (pH 7.4) were obtained by 10 repeated extrusions through syringe needles of successively
smaller sizes, from 22 to 18 gauge, or alternatively by three 30-second strokes of a PowerGen
homogenizer (Fisher Scientific). A final 1% (wt/vol) brain homogenate for inoculation was
obtained by further diluting brain homogenates in 5% (wt/vol) bovine albumin Fraction V
(ICN) and PBS. Using a 27-gauge syringe, 30 µl of 1% brain homogenate were inoculated into
the right parietal lobe, or 200 µl into the peritoneal cavity of mice. Animals were monitored
daily for their clinical status, while the neurologic status was assessed three times per week.
Mice with progressive neurologic dysfunction were euthanized (Carlson et al., 1986).
RESULTS
The experimental paradigm of this study was to investigate the influence of 20 genes on the
incubation time in prion-infected mice in which the gene product was either inactive, absent
or overexpressed.
Modeling disease onset times
To determine the genotype-independent variation in incubation time, we intracerebrally (i.c.)
inoculated over 400 wt FVB/N mice that were divided into 39 groups at 6 different time points
over a five-year period with RML prions (Table S1, Fig. 1). Median incubation times were
calculated for all 39 groups using the Kaplan-Meier function and mice with intercurrent illness
were censored at the time of euthanasia (Kaplan & Meier, 1958). Although these mice were
genetically identical, we observed appreciable variation in median incubation times among
different groups of mice ranging between 103 and 137 days for individual groups. This
variation was not restricted to wt FVB/N mice but also evident in C57BL/6J and CD1 mice
(data not shown). Since the commonly used logrank test does not take into account this type
of experiment-to-experiment variation among genotypically identical mice, we developed a
method to better compare survival curves of prion-diseased mice. Based on our observations,
disease-onset times were well fit using a Weibull regression model with the effects of genotypes
following an accelerated failure time model (Table 2–Table 5) (Cox & Oakes, 1984). This
model accommodates for the fact that in a group of prion-infected mice with the same genotype,
all animals become sick within a very close time interval once single animals start to show
symptoms. To account for experiment-to-experiment variation, we included a gamma
distributed random effect term in the Weibull model that was weighted by the interexperimental
variation observed in RML-inoculated, FVB/N mice (Table S1,Fig. 1) (Glidden & Vittinghoff,
2004,Nielsen et al., 1992). This improved the accuracy of our statistical evaluation and led to
p-values (pWG) that were generally higher than those obtained with the logrank test (pL) (Table
2–Table 5). Effects of experiments in mice expressing neither, one, or both alleles of Il1r1,
Tnfrsf1a and Tnfrsf1b, Cd9, and Prnd were also tested for trend (Vittinghoff et al., 2005). For
a given gene, the trend test delivers increased significance, when incubation times are
increasingly prolonged or shortened based on the number of alleles present. The relative time
for each genotype shown in Table 2–Table 5 was calculated from the accelerated failure time
model, which takes into account both medians and interpercentile ranges of disease-onset times
from genetically modified mice and control mice. All calculations were performed with
Intercooled Stata 9.2 (StataCorp).
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Deficiency in App prolongs prion-incubation times
To analyze the effect of the five AD-related proteins on the incubation time in prion disease,
we inoculated five different mouse models and their respective controls with RML prions
(Table 2). App−/− mice deficient in App expression developed signs of prion disease at ~136
days, whereas wt mice had a median incubation time of 121 days (Fig. 2A). Taking
interexperimental variation into account, this 13% protraction of disease-onset times in
App−/− mice was slight but significant (pWG=0.030). In contrast, lack of Aplp2 expression in
Aplp2−/− mice or overexpression of human APP695 in Tg(APP)6209Kahs mice had no
significant effect on incubation times (Fig. S2A and B). Similarly, expression of human
APOE3 or APOE4 alleles in Apoe−/− mice did not result in significant differences in the
incubation times when compared to Apoe−/− mice (Fig. S2C and D).
Deficiency of a functional IL-1 receptor prolongs prion incubation times
We assayed six genes associated with inflammation for their effect on the prion incubation
time (Table 3). Mice with an ablated interleukin-1 receptor, type I gene (Il1r1−/−) lack a
functional receptor for the proinflammatory cytokines IL-1α and IL-1β and showed 16% longer
incubation times compared to control mice (Fig 2B). Although small, this prolongation was
statistically significant (pWG=0.012).
Mice deficient of the anti-inflammatory cytokine IL-10 had a 19% reduction in the incubation
period compared to wt mice. However, this reduction was observed only in IL10−/− mice on
the C57BL/6J background but not on the 129S1/SvlmJ background (Fig. 2C and D).
None of the other four inflammation-associated genes affected incubation times (Fig. S3A–F).
In two mouse models, inhibited TNF-α signaling resulted in incubation times similar to controls
(Fig. S3A and B). We also found that TGF-β1 signaling had no effect on prion incubation
times, using three different mouse models: Tg(Tgfb1) mice overexpressing TGF-β1,
heterozygous Tg(Tgfb1+/−) mice, and double-transgenic Tg(TβRIIΔk)+/− × Tg(tTA) +/−
Prnp+/− mice expressing a transdominant negative mutant of TGF-β receptor II that disrupts
TGF-β signaling (Fig. S3C and D). Deficiency of CCR2 or CCR5 also did not influence prion
incubation times (Fig. S3E and F).
Proteins associated with protein maintenance do not influence prion incubation times
We tested the influence of four genes relevant to protein expression and maintenance on prion-
incubation times (Table 4). The methionine sulfoxide reductase (Msr) system consisting of
MsrA and MsrB reverts methionine sulfoxide to methionine and thereby protects from
oxidative stress (Moskovitz & Stadtman, 2003). We tested the effect of oxidative stress on
prion replication in MsrA-knockout mice on a regular or on a selenium-depleted diet that further
disables the Msr system by inactivating MsrB, which as a selenoprotein requires selenium to
be fully active. Msra-deficient mice that were kept on a regular or selenium-depleted diet did
not show incubation times significantly different from control mice (Fig. S4A). Incubation
times in Tg(SOD1)3Cje mice that overexpress human superoxide dismutase 1 (SOD1) were
significantly (pWG=0.016) extended by 19% after infection with RML prions (Fig. 2E),
compared to wt littermates. However, this prolongation was not observed when Tg(SOD1)
3Cje mice were infected with the 301V prion strain. Tg(HSP70) mice, which overexpress
human Hsp70, did not show significantly altered incubation times compared to wt littermates
(Fig. 2F). Finally, we addressed whether posttranslational modifications impact PrP conversion
in mice lacking mannoside-b1,4-N-acetylglucosaminyltransferase III (Mgat3/GlcNAcT-III).
In comparison to PrPC, PrPSc contains decreased levels of N-glycans with a bisecting GlcNAc
residue and increased levels of tri- and tetraantennary complex N-glycans, which may result
from a decrease in Mgat3/GlcNAcT-III activity (Rudd et al., 1999). Incubation times in
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Mgat3−/− mice did not differ significantly from wt littermates, even when mice were inoculated
with three different prion strains: RML, ME7, and 301V (Fig. S4B).
Proteins associated with PrP signaling, doppel, and CD9 do not influence prion incubation
times
We investigated the effect of three genes that are seemingly relevant to PrP signaling on prion
replication (Table 5). Incubation times in caveolin-1–deficient mice inoculated either i.c. or
intraperitoneally (i.p.) did not differ significantly from those of FVB/N control mice (Fig. S5A).
Neither mice lacking nor overexpressing Fyn showed altered incubation times upon infection
when compared to wt mice (Fig. S5B and C). Ptpra−/− mice deficient for RPTPα also did not
have significantly changed incubation times (Fig. S5D). As part of this work, we created
Prnd−/− mice that lack expression of the PrP paralog doppel (Dpl), which did not show any
morphological or behavioral defects except for male infertility, as reported earlier (Behrens et
al., 2002). Neither Prnd+/– nor Prnd−/− mice showed significantly modified incubation times
when compared to wt mice (Fig. S5E). We also did not find significantly different incubation
times from Cd9−/− mice, heterozygous Cd9+/− mice, or wt mice after i.c. inoculation with RML
prions (Fig. S5F). Because CD9 is present on the cell surface of lymphocytes, we also
inoculated Cd9−/− and wt mice i.p. with RML prions. Incubation times after i.p. inoculation
were not significantly different.
DISCUSSION
The identification of genes that contribute to prion pathogenesis is of paramount importance
for understanding prion diseases. Although many PrP-interacting proteins have been identified,
only few have been shown to influence prion replication (Schmitt-Ulms et al., 2004,
Westergard et al., In press). To prove that a gene contributes to prion pathogenesis, its
inactivation, absence, or overexpression should affect prion replication as evidenced from
experiments in inbred mice and yeast (Carlson et al., 1988, Stephenson et al., 2000, Wickner
et al., 2007). We analyzed a series of candidate genes with importance in AD, inflammation,
cell signaling, and other cellular functions for their effect on prion pathogenesis. We modeled
disease-onset times after a Weibull regression model that included a gamma distributed random
effect to account for interexperimental variation. Based on our statistical model, only very few
from among 20 candidate genes moderately but significantly affected prion pathogenesis.
We show that knockout of App protracts the onset of prion disease by 13%. While the
underlying mechanism is unclear, its elucidation is likely to promote our understanding of the
neurodegenerative processes in prion disease as well as in AD, both of which share many
common features (DeArmond, 1993). In AD, cleavage of APP gives rise to pathogenic Aβ
peptides that are rich in β-sheet conformation and that can form amyloid plaques in the CNS
similar to PrPSc.
Cytokines and their receptors are key mediators of inflammatory as well as anti-inflammatory
responses and are often found to be upregulated in a multitude of neurodegenerative conditions,
including trauma, stroke, AD, and prion disease. Of six candidate genes that had previously
been reported to be upregulated during prion disease, only interruption of IL-1 signaling mildly
but significantly prolonged disease-onset times by 16%. Our results agree with a study
reporting prolonged incubation times in Il1r1-knockout mice after i.c. infection with at least
~15-fold lower concentrations of mouse-adapted 138A scrapie prions (Schultz et al., 2004).
The prolonged incubation time likely occurs by delaying astrocytic gliosis, as IL-1R1 is mainly
expressed on astrocytes and oligodendrocytes in the CNS and Il1r1−/− mice show reduced
inflammatory responses (Brogi et al., 1997, Labow et al., 1997, Tomozawa et al., 1995).
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Consistent with other studies, abrogated TNF-α or TGF-β signaling did not affect prion
pathogenesis after i.c. inoculation (Klein et al., 1997, Mabbott et al., 2000). In Il10−/− mice,
we observed a 19% reduction in the incubation time on a C57BL/6J background, but no change
on a 129S1/SvlmJ background. Differences in the genetic background of these two inbred
mouse strains likely explain the different incubation times we observed: While all Il10−/− mice
are anemic, growth retarded and develop chronic enterocolitis to intestinal antigens (Kuhn et
al., 1993), Il10−/− mice on the C56BL/6J background have less inflammation and fewer
adenocarcinomas than mice on the 129Sv background (Berg et al., 1996). Our results make it
difficult to draw a firm conclusion about the role of IL-10 in prion pathogenesis but severely
contrast an earlier report in which a >50% reduction in incubation time was reported for
Il10−/− mice on a 129S1/SvlmJ background (Thackray et al., 2004).
Prion disease is accompanied by activation and recruitment of microglia to sites of prion
replication (Guiroy et al., 1994). CCR2 and CCR5 are expressed on microglia and functional
in their activation and recruitment through interaction with chemokine (C-C motif) ligand 2
(CCL2) and CCL5 (Albright et al., 1999, El Khoury et al., 2007). Although survival times of
Ccl2−/− mice infected with ME7 prions were reported to be prolonged (Felton et al., 2005), we
failed to detect an effect on survival in Ccr2−/− and Ccr5−/− mice infected with RML prions.
How ablation of Ccl2 but not Ccr2 can affect survival times in prion disease is unclear, since
CCR2 is the only established high-affinity receptor for CCL2 (Charo et al., 1994). This
disparity may be attributed to infection with different prion strains of different titers or to
problematic statistical analysis of survival times in Ccl2−/− mice. It remains to be determined
if either CCR2 or CCR5 can compensate for the other’s activity in microglial activation and if
incubation times would be prolonged in Ccr2–Ccr5 double-knockout mice.
Our studies also clearly show that the formation of methionine oxides does not play a critical
role in prion pathogenesis. Because certain methionine residues in PrPC can be oxidized, it was
suggested that PrPC may protect from oxidative stress (Wong et al., 1999). Disabling the Msr
system, which reverts methionine sulfoxide to methionine, increases sensitivity to oxidative
stress resulting in reduced life span, elevated levels of hippocampal neurodegeneration, Aβ
deposition and tau phosphorylation (Pal et al., 2007). MsrA-knockout mice without a functional
Msr system (Moskovitz & Stadtman, 2003) showed incubation times similar to controls.
Furthermore, our studies show that the production of free radicals may affect the progression
of disease in a strain-dependent fashion. PrPC has been controversially discussed to have SOD
activity and that loss of this putative function by its conversion to PrPSc may contribute to prion
disease (Hutter et al., 2003, Wong et al., 1999). While disabling the Msr system did not affect
prion pathogenesis, Tg(SOD)3Cje mice overexpressing human SOD1 showed prolonged
incubation times when inoculated with RML prions, but not when injected with 301V prions.
In contrast to RML prions, the 301V strain replicates very slowly in mice expressing mouse
PrP-A and PrPSc deposits accumulate only relatively late during pathogenesis. This may cause
less immediate inflammation and thus less free radical production (Farquhar et al., 1996). A
protective effect of increased SOD activity may only be visible with a fast-replicating strain,
such as RML prions where PrPSc deposits, inflammation, and free-radical production appear
relatively early after infection.
While CD9 ablation did not affect incubation times, we cannot exclude that CD81, which shares
approximately 65% sequence similarity with CD9, can compensate for the PrP-related
functions in Cd9−/− mice. In this case, a Cd9–Cd81 double-knockout mouse might provide
some insight into the role of CD9 and/or CD81 during PrP conversion. While tetraspanins such
as CD9 are known for their exceptional ability to associate with other surface proteins, no
association of CD9 with PrP could be observed (E. Rubinstein, unpublished data).
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In conclusion, our studies underscore the importance of screening genes that may contribute
to prion pathogenesis in in vivo models to establish their function in PrP conversion and
pathogenesis. While all candidate genes tested here were implicated to have a role in prion
pathogenesis in previous studies, only three were shown to affect disease-onset times. We note
that many factors influence these findings, such as the genetic background of the animal model,
the prion strain, inoculum titers, the route of infection, and importantly, the statistical analysis
of incubation times. By using appropriate controls and a rigorous statistical analysis that takes
interexperimental variation into account, we were able to rule out many candidate genes, which
otherwise would have scored as “significant” based on the logrank test alone. Clearly, the
conversion of PrPC to PrPSc involves a complex pathway, the elucidation of which would
benefit treatment of these devastating diseases.
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Survival curves from transmissions of RML prions to six sets of FVB/N mice. Animals in each
set were inoculated on the same day. Median incubation times ranged between 103 and 137
days.
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Survival curves from transmissions of RML prions to (A) App−/− mice; (B) Il1rr−/− mice (black
line) and Il1rI+/− mice (dashed line); (C) B6-IL10−/− mice; (D) 129Sv-IL10−/− mice; and (E)
Tg(SOD1)3Cje (solid lines). In panel E, Tg(SOD1)3Cje mice were also inoculated with 301V
prions (dashed lines). Survival curves of controls are shown by gray lines. Tick marks signify
censored animals.
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Table 1
Proteins tested for their effect on prion replication.
Protein tested Reason of interest Reference Results










Amyloid beta (A4) precursor-like protein (Aplp2)
Human Apolipoprotein E (APOE), ε3 and ε4 alleles
Interleukin 10 (IL-10) elevated in CJDpatients (Stoeck et al.,2005)
Table 3







1994, Sharief et al.,
1999)Tumor necrosis factor (TNF-α)
Transforming growth factor-β1 (TGF-β1) elevated in prion-infected mice (Baker et al., 1999)









(Baker et al., 1999,
Felton et al., 2005,
Lee et al., 2005,
Marella & Chabry,
2004)
Chemokine (C-C motif) receptor 5 (CCR5)




Wong et al., 1999)
Table 4
Methionine sulfoxide reductase B (MsrB)
Human superoxide dismutase 1 (SOD1) putative SODactivity of PrPC (Wong et al., 1999)













(Fiala et al., 2007,
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